Palisade Bio Inc (PALI) - Net Assets
Based on the latest financial reports, Palisade Bio Inc (PALI) has net assets worth $127.36 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($133.31 Million) and total liabilities ($5.95 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Palisade Bio Inc's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $127.36 Million |
| % of Total Assets | 95.53% |
| Annual Growth Rate | N/A |
| 5-Year Change | 1656.69% |
| 10-Year Change | 1041.85% |
| Growth Volatility | 407.01 |
Palisade Bio Inc - Net Assets Trend (2005–2025)
This chart illustrates how Palisade Bio Inc's net assets have evolved over time, based on quarterly financial data. See Palisade Bio Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Palisade Bio Inc (2005–2025)
The table below shows the annual net assets of Palisade Bio Inc from 2005 to 2025. For live valuation and market cap data, see PALI stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $129.38 Million | +1626.91% |
| 2024-12-31 | $7.49 Million | -33.78% |
| 2023-12-31 | $11.31 Million | -9.34% |
| 2022-12-31 | $12.48 Million | +69.44% |
| 2021-12-31 | $7.37 Million | +203.75% |
| 2020-12-31 | $-7.10 Million | -238.49% |
| 2019-12-31 | $5.13 Million | -15.27% |
| 2018-12-31 | $6.05 Million | -28.96% |
| 2017-12-31 | $8.52 Million | -24.85% |
| 2016-12-31 | $11.33 Million | +128.11% |
| 2015-12-31 | $4.97 Million | -71.97% |
| 2014-12-31 | $17.72 Million | +110.49% |
| 2013-12-31 | $8.42 Million | +20.73% |
| 2012-12-31 | $6.97 Million | +320.08% |
| 2011-12-31 | $1.66 Million | -78.87% |
| 2010-12-31 | $7.85 Million | +256.60% |
| 2009-12-31 | $-5.02 Million | -219.32% |
| 2008-12-31 | $4.20 Million | -38.27% |
| 2007-12-31 | $6.81 Million | +338.67% |
| 2006-12-31 | $1.55 Million | +437.32% |
| 2005-12-31 | $-460.17K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Palisade Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11727976200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.59 Million | 1.23% |
| Other Components | $280.51 Million | 216.81% |
| Total Equity | $129.38 Million | 100.00% |
Palisade Bio Inc Competitors by Market Cap
The table below lists competitors of Palisade Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
$302.41 Million |
|
E Split Corp Class A
TO:ENS
|
$302.63 Million |
|
Prenetics Global Ltd
NASDAQ:PRE
|
$302.74 Million |
|
Heung-A Shipping Co. Ltd.
KO:003280
|
$303.02 Million |
|
JSL S.A
SA:JSLG3
|
$302.37 Million |
|
Shanghai Mechanical & Electrical Industry Co Ltd B
SHG:900925
|
$302.30 Million |
|
CLINUVEL PHARMAC.ADRS1
F:UR9A
|
$302.25 Million |
|
AzureWave Technologies Inc
TW:3694
|
$302.18 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Palisade Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,492,000 to 129,380,000, a change of 121,888,000 (1626.9%).
- Net loss of 16,781,000 reduced equity.
- Share repurchases of 19,000 reduced equity.
- New share issuances of 128,219,000 increased equity.
- Other factors increased equity by 10,469,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-16.78 Million | -12.97% |
| Share Repurchases | $19.00K | -0.01% |
| Share Issuances | $128.22 Million | +99.1% |
| Other Changes | $10.47 Million | +8.09% |
| Total Change | $- | 1626.91% |
Book Value vs Market Value Analysis
This analysis compares Palisade Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.76x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $-0.34 | $1.76 | x |
| 2006-12-31 | $72944.97 | $1.76 | x |
| 2007-12-31 | $203.39 | $1.76 | x |
| 2008-12-31 | $113.45 | $1.76 | x |
| 2009-12-31 | $-126.80 | $1.76 | x |
| 2010-12-31 | $156.59 | $1.76 | x |
| 2011-12-31 | $29.75 | $1.76 | x |
| 2012-12-31 | $103.92 | $1.76 | x |
| 2013-12-31 | $100.94 | $1.76 | x |
| 2014-12-31 | $176.34 | $1.76 | x |
| 2015-12-31 | $46.90 | $1.76 | x |
| 2016-12-31 | $1357.79 | $1.76 | x |
| 2017-12-31 | $38.78 | $1.76 | x |
| 2018-12-31 | $22.14 | $1.76 | x |
| 2019-12-31 | $21.59 | $1.76 | x |
| 2020-12-31 | $-29.90 | $1.76 | x |
| 2021-12-31 | $590.95 | $1.76 | x |
| 2022-12-31 | $14.18 | $1.76 | x |
| 2023-12-31 | $24.81 | $1.76 | x |
| 2024-12-31 | $5.29 | $1.76 | x |
| 2025-12-31 | $2.32 | $1.76 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Palisade Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -12.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.04x
- Recent ROE (-12.97%) is above the historical average (-186.19%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 0.00% | -534.38% | 0.54x | 0.00x | $-1.61 Million |
| 2006 | -202.74% | -1184.16% | 0.14x | 1.25x | $-3.30 Million |
| 2007 | -103.72% | -2307.74% | 0.04x | 1.15x | $-7.74 Million |
| 2008 | -281.47% | 0.00% | 0.00x | 1.30x | $-12.25 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.86 Million |
| 2010 | -234.10% | -2506.96% | 0.07x | 1.35x | $-19.17 Million |
| 2011 | -754.24% | -3204.86% | 0.10x | 2.46x | $-12.68 Million |
| 2012 | -145.17% | -2482.66% | 0.05x | 1.25x | $-10.82 Million |
| 2013 | -235.58% | -18029.09% | 0.01x | 2.31x | $-20.67 Million |
| 2014 | -127.71% | -120156.11% | 0.00x | 1.68x | $-24.40 Million |
| 2015 | -420.83% | -200671.98% | 0.00x | 3.01x | $-21.40 Million |
| 2016 | -186.00% | -129724.24% | 0.00x | 1.99x | $-22.21 Million |
| 2017 | -183.98% | -6025.38% | 0.02x | 1.63x | $-16.52 Million |
| 2018 | -81.41% | -1894.23% | 0.03x | 1.27x | $-5.53 Million |
| 2019 | -162.93% | -54254.90% | 0.00x | 1.28x | $-8.86 Million |
| 2020 | 0.00% | -76346.15% | 0.00x | 0.00x | $-9.61 Million |
| 2021 | -361.38% | 0.00% | 0.00x | 1.70x | $-27.35 Million |
| 2022 | -114.27% | -5704.00% | 0.02x | 1.26x | $-15.51 Million |
| 2023 | -108.72% | -4920.00% | 0.02x | 1.24x | $-13.43 Million |
| 2024 | -192.71% | 0.00% | 0.00x | 1.45x | $-15.19 Million |
| 2025 | -12.97% | 0.00% | 0.00x | 1.04x | $-29.72 Million |
Industry Comparison
This section compares Palisade Bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Palisade Bio Inc (PALI) | $127.36 Million | 0.00% | 0.05x | $302.38 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Palisade Bio Inc
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibroste… Read more